INTRODUCTION

Despite the recent advancements in prevention and treatment of stroke, stroke remains the leading cause of disability and the fifth leading cause of death in the US. Especially in those older than 65 years, stroke is a leading cause of death and disability. In the future, due to rapid aging, stroke will have a larger socioeconomic influence (1). Therefore, to aid in prevention, the identification of markers of stroke risk is important. Although stroke has been believed to be a multifactorial disorder with minimal classical patterns of inheritance, accumulating evidence has shown the importance of genetic factors in stroke. Especially, it has been reported that a number of inflammatory mechanisms play a fundamental part in stroke (2); thus, various inflammatory genes showing an association with stroke have received attention as candidate genes (3-11). Also, genetic factors could have an effect on stroke onset, infarct size, and prognosis (12,13). Although several candidate genes have been studied as risk factors for stroke, there are few useful markers for the prevention, diagnosis, and treatment of stroke (14,15).

Interleukin-6 (IL-6) is a potent pleiotropic cytokine that regulates survival and differentiation of neuronal cells. This cytokine plays a substantial role in the immune system. The counterpart, interleukin-6 receptor (IL-6R) complex consists of IL-6R and the interleukin 6 signal transducer (IL6ST/GP130/IL-6 beta), which is associated with many other cytokines. If IL-6 binds to IL-6R, this complex binds to GP130, leading to intracellular signaling cascades (16). IL-6 performs as the main stimulator of C-reactive protein (CRP) production, the levels of which are known to be associated with metabolic syndromes such as obesity and diabetes, as well as with vascular events (17). As an extension of the study of IL-6R, IL-6, and CRP in stroke, the role of IL-6R needs to be elucidated. To our knowledge, there is no study about the associations between IL-6R polymorphisms and ischemic stroke (IS).

Disability after stroke is assessed through formal observation. The National Institutes of Health Stroke Scale (NIHSS) is a neurolologic impairment assessment tool that provides an objective quantified measurement in stroke patients (18,19). Higher scores on NIHSS indicate greater stroke severity. In a previous IL-6 polymorphism study, patients with severe disability (NIHSS ≥ 6) were associated with a specific genotype (20). Stroke rehabilitation outcomes are usually assessed using the Modified Barthel Index (MBI), which is a validated tool scoring independent daily living (21).

The aim of this study was to assess whether single nucleotide polymorphisms (SNPs) of the IL-6R gene were associated with the development, neurologic status, and clinical features of ischemic stroke in the Korean population.

To investigate the contribution of the interleukin-6 receptor (IL-6R) gene single nucleotide polymorphisms (SNPs) to the neurological status of Korean patients with ischemic stroke (IS), two SNPs of the IL-6R gene (rs4845617, 5 UTR; rs2228144, Ala31Ala) were selected. IS patients were classified into clinical phenotypes according to two well-defined scores: the National Institutes of Health Stroke Survey (NIHSS) and the Modified Barthel Index scores. There were 121 IS patients and 291 control subjects. The SNP rs4845617 significantly contributed to the neurological status of patients with IS ($P = 0.011$ in codominant model 2, $P = 0.006$ in recessive model, and $P = 0.008$ in log-additive model). Allele frequencies of rs4845617 and rs2228144 demonstrated no significant difference in IS patients and controls. The AG and GG haplotypes differed between the NIHSS 1 (NIHSS scores < 6) group and the NIHSS 2 (NIHSS scores ≥ 6) group in patients with IS ($P = 0.014$, $P = 0.0024$). These results suggest that rs4845617 of the IL-6R gene is associated with the neurologic status of Korean patients with IS.

Keywords: Interleukin 6-Interleukin 6 Receptor Fusion Protein, Recombinant; Brain Ischemia; Stroke; Neurological Manifestations; Polymorphism
MATERIALS AND METHODS

All participants with stroke were patients who visited the Departments of Rehabilitation Medicine at Kyung Hee Medical Center and Kyung Hee University Hospital at Gangdong. Healthy control subjects were recruited from a general health check-up. IS patients were diagnosed based on magnetic resonance (MR) imaging, computed tomography (CT), or angiography. Exclusion criteria were ischemic heart disease or other causes of cerebrovascular events such as traumatic brain injury, transient ischemic attack, and vascular malformation, etc. The NIHSS and MBI scored were measured in the IS patients. Peripheral blood samples were collected from the subjects, and genomic DNA extraction was performed using a QIAamp® DNA mini kit (QIAGEN, Valencia, CA, USA). The genotypes of the two selected SNPs were determined by direct sequencing (MACROGEN, Seoul, Korea). The following primers were used in the polymerase chain reaction (PCR) amplification: rs4845617 (forward 5'-CTGTTTCGCTCAGGCTGCG-3', reverse 5'-AGAGGCAGACAGCTAATG-3') and rs2228144 (forward 5'-GTAGCCCTGGGCTACCATCA T-3', reverse 5'-GACCTCTGAGGCCAACCTC-3').

PCR consisted of 40 cycles at 94°C for 30 seconds, 58°C for 30 seconds, 72°C for 30 seconds, and 1 cycle at 72°C for 5 minutes. An ABI PRISM 3730XL analyzer (PE Applied Biosystems, Foster City, CA, USA) sequenced the PCR products, and SeqManII software (DNASTAR, Madison, WI, USA) was used to analyze the sequencing data (22).

To obtain odds ratios (ORs), 95% confidence intervals (CIs), and P values adjusted for age and sex as covariates, SNPAnalyzer Pro (ISTECH, Goyang, Korea), Helixtree (Golden Helix, Bozeman, MT, USA), and SNPStats (http://bioinfo.iconcologia.net/index.php?module=Snpstats) were used. The χ² test was used to determine Hardy-Weinberg equilibrium (HWE). A multiple logistic regression analysis was adjusted for age and sex. In terms of increasing risk of disease, an increased specific allele frequency was noted in IS patients compared with the allele frequency of controls. To analyze the association between a polymorphism and disease, a contingency table and χ² test were applied using a prespecified genetic model. The codominant model was the most general model "where the disease risk associated with AB individuals lies between that of AA and BB individuals. In dominant model, with the hypothesis that carrying allele B increased risk of disease (dominant model), the AB and BB genotypes are pooled giving a 2 * 2 table. Alternatively, under a recessive model for allele B, cells AA and AB would be pooled. Additive model is assumed that increased disease risk of γ for AB genotypes and 2 γ for BB genotypes" (23). In this study, codominant model 1 compared major allele homozygotes with heterozygotes, and codominant model 2 compared major allele homozygotes with minor allele homozygotes.

To determine the haplotypes between the two examined SNPs and the clinical features in patients with IS, Haploview version 4.2 (Daly Lab, Cambridge, MA, USA) was used. The statistical significance level was set at P < 0.05.

RESULTS

There were 121 IS patients (mean ± SD, 65.7 ± 12.1 years) and 291 controls (mean ± SD, 63.0 ± 9.3 years). The total IS group consisted of 68 males and 53 females. The control group consisted of 152 males and 140 females. There was a difference in mean age between IS patients and control subjects, but it was not significant (P = 0.30). Therefore, we adjusted the statistical results for age and gender. IS patients were classified into two subgroups according to NIHSS score (NIHSS 1, NIHSS score < 6; and NIHSS 2, NIHSS score ≥ 6) and MBI score (MBI 1, MBI ≤ 60; and MBI 2, MBI score > 60). The numbers of IS patients with NIHSS score < 6 and ≥ 6 were 56 and 57, respectively. The characteristics of the IS and control groups are shown in Table 1. The numbers of IS patients with MBI score ≤ 60 and > 60 were 71 and 25, respectively (data not shown).

The genotype and allele frequencies of the two examined SNPs are shown in Tables 2 and 3, respectively. Two SNPs (rs4845617, 5TUR; rs2228144, Ala31Ala) of the IL-6R gene were in HWE in the IS and control groups, respectively (P > 0.05, data not shown). The genotype and allele frequencies of the two SNPs demonstrated no significant difference in IS cases and controls (Table 2). As shown in Table 3, the SNP rs4845617 was associated with the NIHSS score of IS patients (P = 0.011, OR = 0.24, 95% CI = 0.08-0.72 in codominant model 2, P = 0.006, OR = 0.30, 95% CI = 0.12-0.74 in recessive model, and P = 0.008, OR = 0.48, 95% CI = 0.28-0.84 in log-additive model). In SNP rs4845617, the frequencies of genotype according to NIHSS score of IS patients (NIHSS 1, NIHSS score < 6; NIHSS 2, NIHSS score ≥ 6).
Table 2. Genotype and allele frequencies of the two SNPs (rs4845617, rs2228144) in ischemic stroke patients and control subjects

| SNP        | Type  | Ischemic stroke | Control | Model      | OR (95% CI) | P     | Fisher’s exact P |
|------------|-------|-----------------|---------|------------|-------------|-------|-----------------|
| rs4845617  | G/G   | 29 24.2 91 31.5 |         | Codominant 1 | 1.32 (0.78-2.23) | 0.300 |
| 5’UTR      | A/G   | 59 49.2 133 46.0 |         | Codominant 2 | 1.57 (0.86-2.86) | 0.140 |
|            | A/A   | 32 26.7 65 22.5 |         | Dominant    | 1.40 (0.86-2.29) | 0.170 |
|            |       |                |         | Recessive   | 1.32 (0.80-2.16) | 0.280 |
| AG         |       |                |         | Log-additive | 1.25 (0.93-1.69) | 0.140 |
| rs4845617  | G     | 117 48.8 315 54.5 |         | Dominant    | 1.32 (0.80-2.16) | 0.280 |
|            | A     | 123 51.3 263 45.5 |         | Recessive   | 1.25 (0.93-1.69) | 0.140 |
|            |       |                |         | Log-additive | 1.25 (0.93-1.69) | 0.140 |

Table 3. Genotype and allele frequencies of the two SNPs (rs4845617, rs2228144) in ischemic stroke patients (NIHSS 1, 2) according to NIHSS score

| SNP        | Type  | NIHSS 1 | NIHSS 2 | Model      | OR (95% CI) | P     | Fisher’s exact P |
|------------|-------|---------|---------|------------|-------------|-------|-----------------|
| rs4845617  | G/G   | 18 19.1 | 17 30.4 | Codominant 1 | 0.70 (0.27-1.84) | 0.470 |
| 5’UTR      | A/G   | 24 42.9 | 30 53.6 | Codominant 2 | 0.74 (0.43-1.32) | 0.011 |
|            | A/A   | 22 39.3 | 9 16.1 | Dominant    | 0.47 (0.19-1.16) | 0.098 |
|            |       |         |         | Recessive   | 0.30 (0.12-0.74) | 0.006 |
|            |       |         |         | Log-additive | 0.48 (0.28-0.84) | 0.008 |
| AG         |       |         |         |              |              |       |                 |
| rs2228144  | G/G   | 65 38.5 | 47 26.9 | Codominant 1 | 0.97 (0.35-2.66) | 0.950 |
| Ala31Ala   | A/G   | 20 16.7 | 60 20.6 | Codominant 2 | 0.70 (0.14-3.56) | 0.670 |
|            | A/A   | 2 1.7   | 6 2.1  | Dominant    | 0.75 (0.43-1.32) | 0.320 |
|            |       |         |         | Recessive   | 0.74 (0.15-3.74) | 0.710 |
|            |       |         |         | Log-additive | 0.78 (0.48-1.26) | 0.290 |
| GA         |       |         |         |              |              |       |                 |

Table 4. IL-6R Haplotype frequencies in ischemic stroke patients and control subjects

| Haplotype | Frequency | Ischemic stroke | Control | χ² | P |
|-----------|-----------|-----------------|---------|----|---|
| GG        | 0.459     | 102.3 137.7 275.3 306.7 1.493 | 0.220 |
| AG        | 0.424     | 113.7 126.3 234.7 347.3 3.451 | 0.060 |
| GA        | 0.069     | 14.7 225.3 41.8 540.2 0.299 | 0.580 |
| AA        | 0.048     | 9.3 230.7 30.2 551.8 0.638 | 0.420 |

Table 5. Haplotype frequencies in ischemic stroke patients according to NIHSS scores

| Haplotype | Frequency | NIHSS 1 | NIHSS 2 | χ² | P |
|-----------|-----------|---------|---------|----|---|
| AG        | 0.489     | 63.5 48.5 45.1 66.9 6.044 | 0.014 |
| GG        | 0.417     | 35.5 76.5 57.9 54.1 9.203 | 0.002 |
| GA        | 0.065     | 8.5 103.5 6.1 105.9 0.419 | 0.520 |
| AA        | 0.033     | 4.5 107.5 2.9 109.1 0.361 | 0.550 |

Table 6. Haplotype frequencies in ischemic stroke patients according to MBI scores

| Haplotype | Frequency | MBI 1 | MBI 2 | χ² | P |
|-----------|-----------|-------|-------|----|---|
| AG        | 0.489     | 65.8 74.2 27.1 22.9 0.76 | 0.380 |
| GG        | 0.417     | 61.2 78.8 17.9 32.1 0.945 | 0.330 |
| GA        | 0.062     | 8.8 131.2 3.1 46.9 0.001 | 0.980 |
| AA        | 0.032     | 4.2 135.8 1.9 48.1 0.079 | 0.780 |

The frequency of the AG haplotype was higher in the NIHSS 1 group, and that the NIHSS 1 and NIHSS 2 groups in IS patients. However, in SNP rs2228144, the genotype and allele frequencies did not correlate with the NIHSS score of the IS group (Table 3). Furthermore, rs4845617 and rs2228144 had no correlation with MBI score in the IS group (data not shown).
of the GG haplotype was higher in the NIHSS 2 group of IS patients ($P = 0.014, P = 0.0024$, respectively). However, the haplotype frequencies found no significant difference by MBI scores (Table 6).

**DISCUSSION**

Ischemic stroke is known to be a heterogeneous multifactorial disease (24). Although conventional risk factors such as hypertension, diabetes, dyslipidemia and smoking account for a significant proportion of these stroke events, a considerable portion remains insufficiently explained by these factors (25,26). As risk factors for stroke, several genetic factors have been studied; however, there are few useful markers for prevention, diagnosis, and treatment of stroke (26). Therefore, increasing our understanding of risk factors including genetic components would allow us to predict the risk better, identification of novel stroke mechanisms, and new therapeutic approaches using genetic factors (27).

Several studies have reported the relationship between SNPs and stroke risk in Korea. Some of these SNPs include apolipoprotein E (3), 5-methyltetrahydrofolate-homocysteine methyltransferase (6), interleukin 4 (11), interleukin-1 receptor antagonist, tumor necrosis factor, interleukin 1 beta (8), neuropeptide Y (5), peroxisome proliferator-activated receptor gamma (9), phosphodiesterase 4D cAMP-specific chemokine (C-C motif) ligand 5 (4), thromboxaneA2 receptor, and thromboxane A synthase 1 (platelet) (10).

Several SNPs have been identified in the IL-6R gene, associated with carotid plaque (28), CRP (17,29) and obesity or diabetes (30-33). However, there has been no study of polymorphisms of the IL-6R gene in relation to stroke. Carotid plaque is assumed to be associated with increased stroke risk. In a genetic study in a Dominican population, IL-6R was suggested to be a related gene associated with carotid plaque (28).

Elevated CRP level predicts risk of stroke (17). IL-6 has been shown to have a positive correlation with CRP and to predict the risk of vascular events. The polymorphism of IL-6R gene is linked with CRP expression and plasma IL-6 level (34). Lu Qi et al. (35) demonstrated that the IL-6R variants (rs6884439, rs4845622, rs8192284, rs4329505) are significantly associated with plasma CRP level, independent of IL-6 level. In addition, the IL-6R variant interacts with CRP in relation to diabetes risk. In another study, the IL-6R gene (rs4845617) was suggested to play an important role in the pathogenesis of dyslipidemia and atherosclerosis (36). We identified SNPs of IL-6R, in coding regions near the promoter region, that had greater than 0.1 heterozygosity and greater than 0.1 minor allele frequency. For rs4845617, heterozygosity is 0.471, and minor allele frequency is 0.3804; for rs2228144, heterozygosity is 0.208, and minor allele frequency is 0.1178.

This is the first report to identify an association between SNPs of the IL-6R gene associated with risk of stroke and the clinical features of stroke. The two SNPs (rs4845617 and rs2228144) were not associated with development or daily activities of IS. However, our results revealed that SNP rs4845617 contributes to the neurologic status of IS patients. The mechanisms remain on the effects of IL-6R gene polymorphisms on stroke severity remain unclear. Compared with previous SNPs studies, the sample size in this study was relatively small. Therefore, other stroke risk factors analyses could be included while sample size became smaller after dividing groups with regard to hypertension, diabetes, dyslipidemia, and smoking history in this study. Further studies with larger sample size are necessary to elucidate this result.

In summary, two SNPs of the IL-6R gene (rs4845617, rs2228144) were analyzed in Korean ischemic stroke patients. The frequencies of genotype and alleles of the two SNPs demonstrated no significant difference in IS cases and controls. Therefore, the two SNPs are not associated with development of IS. However, in SNP rs4845617, the frequencies of genotypes according to NIHSS score are statistically different, and the A allele frequency in the mild stroke patients is significantly higher than an allele frequency in the severe stroke patients. This indicates that SNP rs4845617 is associated with the neurologic status evaluated by NIHSS in patients with IS. In addition, the A allele of SNP rs4845617 might have a protective effect against neurologic deficit in IS patients.

**DISCLOSURE**

The authors have no potential conflicts of interest to disclose.

**AUTHOR CONTRIBUTION**

Study design and literature review: Kim DH, Yoo SD, Lee SA, Chung JH. Data management and analyses: Kim DH, Chon J, Yun DH, Kim HS, Park HJ, Kim SK. Interpretation of the findings and preparation of the manuscript: Kim DH, Kim HS, Kim SK, Chung JH, Kang JK, Lee SA. Manuscript preparation: Kim DH, Yoo SD, Chon J, Yun DH, Kim HS, Park HJ, Kim SK, Kang JK, Lee SA. Agreement with final manuscript and submission: all authors.

**ORCID**

Dong Hwan Kim  http://orcid.org/0000-0002-3812-5509
Seung Ah Lee  http://orcid.org/0000-0002-3426-6259

**REFERENCES**

1. Andrawes WF, Bussy C, Belmin J. Prevention of cardiovascular events in elderly people. Drugs Aging 2005; 22: 859-76.
2. Tuttolomondo A, Di Raimondo D, di Sciaccia R, Pinto A, Licata G. Inflammatory cytokines in acute ischemic stroke. *Carr Pharm Des* 2008; 14: 3574-89.

3. Kang SY, Lee WI. Apolipoprotein e polymorphism in ischemic stroke patients with different pathogenetic origins. *Korean J Lab Med* 2006; 26: 210-6.

4. Kim MK, Kim JH, Choi SM, Lee SH, Park MS, Cho KH. Phosphodiesterase 4D gene and risk of noncardiogenic ischemic stroke in a Korean population. *J Korean Med Sci* 2009; 24: 307-10.

5. Kim NS, Ko MM, Cha MH, Oh SM, Bang OS. Age and sex dependent genetic effects of neuropeptide Y promoter polymorphism on susceptibility to ischemic stroke in Koreans. *Clin Chim Acta* 2010; 411: 1243-7.

6. Kim OJ, Hong SP, Ahn JY, Hong SH, Hwang TS, Kim SO, Yoo W, Oh D, Kim NK. Influence of combined methionine synthase (MTHFR 677C > T) polymorphisms to plasma homocysteine levels in Korean patients with ischemic stroke. *Yonsei Med J* 2007; 48: 201-9.

7. Kim Y, Kim JH, Nam YJ, Kong M, Kim YJ, Yu KH, Lee BC, Lee C. Klotho is a genetic risk factor for ischemic stroke caused by cardioembolism in Korean females. *Neurosci Lett* 2006; 407: 189-94.

8. Lee BC, Ahn SY, Dooy HK, Yim SY, Lee IH, Jin SY, Hong SJ, Lee SH, Kim SD, Seo JC, et al. Susceptibility for ischemic stroke in Korean population is associated with polymorphisms of the interleukin-1 receptor antagonist and tumor necrosis factor-alpha genes, but not the interleukin-1beta gene. *Neurosci Lett* 2004; 357: 33-6.

9. Lee BC, Doo HK, Ahn SY, Byun SH, Kim SI, Park HK, Hong M, Ha E, Yim SY, Yim C, et al. Peroxisome proliferator-activated receptor-gamma Pro12 Ala polymorphism is associated with the susceptibility to ischemic stroke in Taeeumini classified by Sasang medicine. *Neurol Rev* 2007; 29 Suppl 1: S32-7.

10. Park SA, Park BL, Park JH, Lee TK, Sung KB, Lee YK, Chang HS, Park CS, Shin HD. Association of polymorphisms in thromboxane A2 receptor and thromboxane A synthase 1 with cerebral infarction in a Korean population. *BMB Rep* 2009; 42: 200-5.

11. Um JI, Kim HM. Polymorphisms of RANTES and IL-4 genes in cerebral infarction. *J Mol Neurosci* 2009; 37: 1-5.

12. Meschia JF. Clinically translated ischemic stroke genomics. *Stroke* 2004; 35: 2735-9.

13. Mallolos J, Hurtado O, Castellanos M, Blanco M, Sobrino T, Serena J, Vivancos J, Castillo I, Lizasoain I, Moro MA, et al. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke. *J Exp Med* 2006; 203: 711-7.

14. Dijkstra B. Genetics of ischemic stroke. *Lancet Neurol* 2007; 6: 1-9.

15. Yamada Y, Metoki N, Yoshida H, Satoh K, Kato K, Hibi H, Yoko K, Watanabe S, Ichihara S, Aoyagi Y, et al. Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals. *Stroke* 2008; 39: 2211-8.

16. Wang M, Song H, Jia J. Interleukin-6 receptor gene polymorphisms were associated with sporadic Alzheimer’s disease in Chinese Han. *Brain Res* 2010; 1327: 1-5.

17. Ridker PM, Rifai N, Rose I, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med* 2002; 347: 1557-65.

18. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH stroke scale. *Arch Neurol* 1989; 46: 660-2.

19. Muir KW, Weir CJ, Murray GJ, Powey C, Lees KR. Comparison of neurological scales and scoring systems for acute stroke prognosis. *Stroke* 1996; 27: 1817-20.

20. Greisenegger S, Endler G, Haering D, Schillinger M, Lang W, Lalouschek W, Mannhalter C. The (-174) G/C polymorphism in the interleukin-6 gene is associated with the severity of acute cerebrovascular events. *Thromb Res* 2003; 110: 181-6.

21. Wade DT. Measurement in neurological rehabilitation. *Carr Opin Neurol Surg* 1992; 5: 682-6.

22. Park HK, Jo DJ. Polymorphisms of integrin, alpha 6 contribute to the development and neurologic symptoms of intracerebral hemorrhage in Korean population. *J Korean Neurol Soc* 2011; 50: 293-8.

23. Lewis CM. Genetic association studies: design, analysis and interpretation. *Brief Bioinform* 2002; 3: 146-53.

24. Matarin M, Singleton A, Hardy J, Meschia J. The genetics of ischaemic stroke. *Intern Med* 2010; 267: 139-55.

25. Bevan S, Markus HS. Genetics of common polygenic ischaemic stroke: current understanding and future challenges. *Stroke Res Treat* 2011; 2011: 179061.

26. Hassan A, Markus HS. Genetics and ischaemic stroke. *Brain* 2000; 123: 1784-812.

27. Markus HS. Stroke genetics. *Hum Mol Genet* 2011; 20: R124-31.

28. Gardener H, Beecham A, Cabral D, Yanuck D, Slifer S, Wang L, Blanton SH, Sacco RL, Joo SH, Rundek T. Carotid plaque and candidate genes related to inflammation and endothelial function in Hispanics from northern Manhattan. *Stroke* 2011; 42: 889-96.

29. Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. *Diabetologia* 2004; 47: 1403-10.

30. Wollford JK, Colligan PB, Gruber JD, Bogardus C. Variants in the interleukin 6 receptor gene are associated with obesity in Pima Indians. *Mol Genet Metab* 2003; 80: 338-43.

31. Hamid YH, Ubrhammer SA, Jensen DP, Glümer C, Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O. Variation in the interleukin-6 receptor gene associates with type 2 diabetes in Danish whites. *Diabet Med* 2004; 53: 3424-5.

32. Wang H, Zhang Z, Chu W, Hale T, Cooper JJ, Elbein SC. Molecular screening and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity. *J Clin Endocrinol Metab* 2005; 90: 1123-9.

33. Estove E, Villuendas G, Mallolos J, Vendrell J, López-Bermúdez A, Rodríguez M, Recasens M, Ricart W, San Millán JL, Escobar-Morreale H, et al. Polymorphisms in the interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. *Clin Endocrinol (Oxf)* 2006; 65: 88-91.

34. Ridker PM, Pare G, Parker A, Zee KY, Buring JE, Kwaterowski D, Cook NR, Miletich JP, Chasman DI. Loci related to inflammation and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity. *J Clin Endocrinol Metab* 2005; 90: 1123-9.